Orphanet: Etude multicentrique, prospective, en ouvert, non contrôlée, de phase I II, pour évaluer l_efficacité et la tolérance de la doxorubicine liposomale Doxorubicine GP Pharm en traitement de première ligne des sarcomes des tissus mous chez les patient âgés de 45 ans et plus.
x

Search for a clinical trial

* (*) mandatory field

Multicenter, prospective, open-label, uncontrolled study in patients aged 45 years or older to evaluate the efficacy and safety of Liposomal Doxorubicin (Doxorubicin GP-Pharm) in first-line treatment in soft-tissue sarcomas (Phase I-II) - FR

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : Yes
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : European
  • Sponsor : Gp-pharm s.a
  • Website
    • Phase : I - II
  • Sponsor of clinical trial

  • GP-PHARM S.A
  • GP-Pharm S.A
  • Pol. Ind. Els Vinyets els Fogars 2 Carretera Comarcal 244, km 22
  • 08777 ST QUINT DE MEDIONA
  • SPAIN
  • More information
  • Phone  : 34 93 638 80 00
  • Fax  : 34 93 638 93 93
  • Website
Last update: September 2014

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.